In the United States, the FDA approved ivosidenib for IDH1 mutations and pemigatinib, infigratinib, and futibatinib for FGFR2 fusions, alongside tumor-agnostic treatments for mismatch repair deficiency, NTRK fusions, ERBB2 amplifications, BRAF V600E mutations, and RET fusions. Here, FGFR2 is linked to neoplasm.